Market Overview

Bernstein Says Generic Copaxone Win Could Help Momenta Break through $20 Level

Share:
Related MNTA
12 Biggest Mid-Day Losers For Monday
Benzinga's Top Upgrades, Downgrades For May 22, 2017
Related TEVA
It's Easy To Be Skeptical Of Mylan, But Don't Ignore This Pending PDUFA Date
Vetr Issues Strong Buy As Teva Trends Down

Momenta Pharmaceuticals (NASDAQ: MNTA) shares spiked sharply Friday following news of a legal ruling invalidating Teva Pharmaceutical's (NYSE: TEVA) patents on Copaxone in 2015 and partly invalidating its 2014 patents.

Bernstein analyst Ronny Gal sees a 75 percent chance of the court decision being favorable for Momenta. The ruling could open the door to Momenta introducing a generic Copaxone within the next few months, according to Gal.

If Momenta is able to introduce the first generic Copaxone by May 2014, Gal believes shares could be valued at $30. This is nearly twice the $15.35 level shares were trading at prior to Friday's spike.

Gal believes a later release by Q4 2015 could spell upside of 30 percent from current levels to $23 per share.

Gal rates Momenta at Outperform with a $20 price target.

Latest Ratings for MNTA

DateFirmActionFromTo
May 2017BarclaysDowngradesOverweightEqual-Weight
Feb 2017Leerink SwannDowngradesOutperformMarket Perform
Nov 2016Aegis CapitalInitiates Coverage OnHold

View More Analyst Ratings for MNTA
View the Latest Analyst Ratings

Posted-In: Analyst Color News FDA Legal Analyst Ratings Movers

 

Related Articles (MNTA + TEVA)

View Comments and Join the Discussion!